Retinitis Pigmentosa Therapy Highlighted at CIRM Symposium

The California Institute for Regenerative Medcine’s (CIRM’s) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the clinic. One of our co-founders, Dr. Henry Klassen, spoke about his long efforts to develop a retinitis pigmentosa therapy and how that treatment is doing in clinical trials. Aftewards, Kristin MacDonald, the first patient treated with jCell in our phase 1/2a clinical trial, discussed what the treatment has meant to her. See their presentations below.



Leave a comment